Zymeworks (ZYME) Deferred Taxes (2021 - 2026)
Zymeworks (ZYME) posted Deferred Taxes of $2.2 million for Q1 2026, up 256.03% sequentially from -$1.4 million in Q4 2025, and up 436.59% YoY from $410000.0 in Q1 2025.
Analysis
Zymeworks (ZYME) Deferred Taxes (2021 - 2026) Analysis & Trends
Zymeworks has reported Deferred Taxes for 6 years, with the latest figure at $2.2 million in Q1 2026.
- Quarterly Deferred Taxes rose 436.59% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $845000.0 (up 364.89% YoY) and the FY2025 annual result came in at -$945000.0, down 36.76% from the prior year.
- Deferred Taxes grew to $2.2 million in Q1 2026 per ZYME's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Deferred Taxes peaked at $2.2 million in Q1 2026 and troughed at -$1.9 million in Q4 2022.
- A 5-year average of -$36411.8 and a median of $38000.0 in 2024 frame the typical range for Deferred Taxes.
- The sharpest annual moves came in 2022 and 2025: Deferred Taxes tumbled 249.76% in 2022, then surged 978.95% in 2025.
- Over 5 years, Deferred Taxes stood at -$1.9 million in 2022, then surged by 151.41% to $967000.0 in 2023, then tumbled by 216.55% to -$1.1 million in 2024, then retreated by 25.11% to -$1.4 million in 2025, then jumped by 256.03% to $2.2 million in 2026.
- According to Business Quant data, Deferred Taxes over the past three periods registered $2.2 million, -$1.4 million, and $170000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 10 | Zymeworks | 2.15 Bn | 1.88 Bn | - | -265,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -265,000.00 |
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | -1.41 Mn |
| Sep 30, 2025 | 170,000.00 |
| Jun 30, 2025 | -115,000.00 |
| Mar 31, 2025 | 410,000.00 |
| Dec 31, 2024 | -1.13 Mn |
| Sep 30, 2024 | 204,000.00 |
| Jun 30, 2024 | 194,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Dec 31, 2023 | 967,000.00 |
| Sep 30, 2023 | -95,000.00 |
| Jun 30, 2023 | -106,000.00 |
| Mar 31, 2023 | -9,000.00 |
| Dec 31, 2022 | -1.88 Mn |
| Sep 30, 2022 | 411,000.00 |
| Jun 30, 2022 | 265,000.00 |
| Mar 31, 2022 | -735,000.00 |
| Dec 31, 2021 | 1.26 Mn |